Foundation medicine name Roche SVP as new CEO
Roche subsidiary, Foundation Medicine, today announced the appointment of Roche’s senior vice president in global oncology, Cindy Perettie as the company’s new CEO.
The appointment, effective February 4, 2019, will see Periette succeed Troy Cox. Having most recently served as the SVP in global oncology product strategy for Roche’s Oncology unit, Periette brings to the role more than two decades of scientific and commercial experience.
“Cindy brings proven global, strategic, and operational biopharma leadership and oncology expertise to lead Foundation Medicine through the next phase of its growth,” said Troy Cox, chief executive officer at Foundation Medicine.
Periette has led successful product launches for both Roche and Genentech across the companies’ oncology portfolio, in areas including those of breast cancer and haematology. Having begun her tenure at Genentech, Periette has taken on roles of increasing seniority since joining in 2004.
“As we look ahead, the advancements across our molecular information portfolio position the Company to continue to lead in precision oncology and Cindy is well poised to accelerate our work to bring these advances forward and transform cancer care for patients. I look forward to collaborating with her and the senior management team in transitioning the chief executive officer role, as we together work toward supporting the Company’s mission. My time at Foundation Medicine has been one of the most rewarding of my career. The mission, the people, and the impressive progress we have made together has been life-changing for me. I am grateful to carry that with me into my next chapter,” Cox added.
A graduate of State University of New York College at Potsdam, Periette began her career as a research associate at John Hopkins University, before taking on a research scientist associate director role at Chiron Corporation.